B-cell Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for B-cell Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL) [Phase 2]
Phase 2 study evaluating obecabtagene autoleucel as consolidation therapy in newly diagnosed high-risk B-cell acute lymphoblastic leukemia; …
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction [NA]
Clinical trial update on cytokine-induced killer (CIK) cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia, assessin…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia [EARLY_Phase 1]
An early-phase study of SYNCAR-100 is investigating its use in relapsed/refractory B-cell acute lymphoblastic leukemia. The trial is current…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia [Phase 3]
Phase 3 clinical trial evaluating imatinib mesylate in combination with chemotherapy for newly diagnosed Philadelphia chromosome-positive ac…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Long-term Follow up Local Registry Study of Kymriah in South Korea
This clinical trial update reports a long-term follow-up local registry study of Kymriah in South Korea. Recruitment is ongoing for patients…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 study evaluating subcutaneous blinatumomab with low-intensity chemotherapy for older patients with newly diagnosed B-cell acute lymp…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL [Phase 1]
A Phase 1 study is evaluating a triplet of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for relapsed B-cell acute lymphoblastic leuk…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL [Phase 1]
A Phase 1 study of ThisCART19A in relapsed/refractory B-cell acute lymphoblastic leukemia has completed, reporting on safety, efficacy, and …
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma [EARLY_Phase 1]
This is an early-phase (Phase 1) clinical trial update for Iomab-ACT, which combines 131-I-labeled apamistamab with CD19-targeted CAR T-cell…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R [NA]
A single-arm, non-randomized pilot trial to evaluate the safety of autologous anti-CD19 CAR-T cells (ARI-0001) and the feasibility of local …
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease [Phase 2]
Phase 2 clinical trial update evaluating Besponsa (Inotuzumab ozogamicin) for B-cell acute lymphoblastic leukemia with positive minimal resi…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL [EARLY_Phase 1]
An early-phase 1 clinical trial of JY509 universal NK cell injections for relapsed/refractory pediatric B-cell acute lymphoblastic leukemia …
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL [Phase 1]
A Phase 1 clinical trial evaluating BAFFR-targeting CAR-T cells for relapsed or refractory B-cell acute lymphoblastic leukemia is currently …
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Study of YK012 in B-cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Clinical trial update for YK012 in B-cell acute lymphoblastic leukemia (Phase 1/Phase 2) by Excyte Biopharma Ltd; the study is currently rec…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) [Phase 2]
Phase 2 trial update evaluating a second, early reinfusion of tisagenlecleucel in children and young adults with B-cell acute lymphoblastic …
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma [Phase 1]
Phase 1 trial evaluating an in vivo CAR-T therapy targeting CD19 and BAFF-R for relapsed/refractory B-cell acute lymphoblastic leukemia and …
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) [Phase 1]
Phase 1 dose-escalation and dose-expansion study to evaluate the safety of Azer-cel (PBCAR0191) in relapsed/refractory non-Hodgkin lymphoma …
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Venetoclax Plus Inotuzumab for B-ALL [Phase 1]
This is an update on a Phase 1 trial of venetoclax plus inotuzumab ozogamicin for B-cell acute lymphoblastic leukemia and B-cell lymphoma; t…
-
CLINICAL_TRIALS other · 2026-01-16Clinical Trial Update: AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia [Phase 1, Phase 2]
AZD0486 is being studied as a monotherapy in B-cell acute lymphoblastic leukemia in Phase 1/2 trials and the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating low-intensity chemotherapy plus venetoclax for relapsed or refractory B-cell and T-cell acute lymph…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors [EARLY_Phase 1]
This is an early-phase clinical trial update for LV009 injection evaluating its use in CD19-positive recurrent/refractory B-cell acute lymph…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL [EARLY_Phase 1]
An early-phase Phase 1 study of a novel TLR2-containing CAR-T cell therapy targeting CD19 and CD22 for relapsed/refractory B-cell acute lymp…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) [EARLY_Phase 1]
An early Phase 1 clinical trial of JY231 injection for B-cell acute lymphoblastic leukemia is currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) [Phase 1, Phase 2]
A phase 1/2 pediatric trial is evaluating autologous HuCART19 T cells produced with the CliniMACS Prodigy platform for B-cell acute lymphobl…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL [Phase 2]
A Phase 2 clinical trial evaluating low-dose chemotherapy combined with immuno-targeted therapies for newly diagnosed adult Philadelphia chr…